Organon & Co (NYSE: OGN)’s stock price has decreased by 0.00 compared to its previous closing price of 8.71. However, the company has seen a -0.11% decrease in its stock price over the last five trading sessions. seekingalpha.com reported 2025-05-12 that Initiate Strong Buy on Organon & Co. with $26.4 PT, driven by cost savings, Nexplanon momentum, and biosimilars diversification offsetting Established Brands LOE. Forecasted EPS of $4.00 (FY25; +20.1% Y/Y) and $4.40 (FY26; +10.0%), well above consensus, supported by operational leverage and dividend cut for deleveraging. Transformational cost savings of >$200M by FY25 and $275M by FY26, driving margin expansion and multi-year EPS acceleration.
Is It Worth Investing in Organon & Co (NYSE: OGN) Right Now?
Organon & Co (NYSE: OGN) has a price-to-earnings ratio that is above its average at 3.01x. The stock has a 36-month beta value of 0.67. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 3 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for OGN is 259.02M, and at present, short sellers hold a 7.61% of that float. On May 13, 2025, the average trading volume of OGN was 5.18M shares.
OGN’s Market Performance
The stock of Organon & Co (OGN) has seen a -0.11% decrease in the past week, with a -23.80% drop in the past month, and a -42.09% fall in the past quarter. The volatility ratio for the week is 8.22%, and the volatility levels for the past 30 days are at 6.44% for OGN. The simple moving average for the past 20 days is -18.17% for OGN’s stock, with a -46.71% simple moving average for the past 200 days.
Analysts’ Opinion of OGN
JP Morgan, on the other hand, stated in their research note that they expect to see OGN reach a price target of $20, previously predicting the price at $18. The rating they have provided for OGN stocks is “Underweight” according to the report published on September 06th, 2024.
Goldman gave a rating of “Neutral” to OGN, setting the target price at $16 in the report published on November 03rd of the previous year.
OGN Trading at -32.53% from the 50-Day Moving Average
After a stumble in the market that brought OGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -62.29% of loss for the given period.
Volatility was left at 6.44%, however, over the last 30 days, the volatility rate increased by 8.22%, as shares sank -22.09% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -41.58% lower at present.
During the last 5 trading sessions, OGN fell by -0.11%, which changed the moving average for the period of 200-days by -59.73% in comparison to the 20-day moving average, which settled at $10.64. In addition, Organon & Co saw -41.62% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at OGN starting from Falcione Aaron, who purchase 5,500 shares at the price of $8.77 back on May 07 ’25. After this action, Falcione Aaron now owns 62,974 shares of Organon & Co, valued at $48,235 using the latest closing price.
Weaver Kirke, the Gen. Counsel & Corp. Secy. of Organon & Co, purchase 8,045 shares at $9.21 during a trade that took place back on May 06 ’25, which means that Weaver Kirke is holding 52,489 shares at $74,054 based on the most recent closing price.
Stock Fundamentals for OGN
Current profitability levels for the company are sitting at:
- 0.22 for the present operating margin
- 0.57 for the gross margin
The net margin for Organon & Co stands at 0.12. The total capital return value is set at 0.13. Equity return is now at value 254.24, with 5.99 for asset returns.
Based on Organon & Co (OGN), the company’s capital structure generated 0.94 points at debt to capital in total, while cash flow to debt ratio is standing at 0.1. The debt to equity ratio resting at 16.52. The interest coverage ratio of the stock is 2.72.
Currently, EBITDA for the company is 1.61 billion with net debt to EBITDA at 5.61. When we switch over and look at the enterprise to sales, we see a ratio of 1.7. The receivables turnover for the company is 4.32for trailing twelve months and the total asset turnover is 0.48. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.67.
Conclusion
To sum up, Organon & Co (OGN) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
